跳至主要内容
临床试验/PACTR202009811610400
PACTR202009811610400尚未招募未知

Continuous vs. intermittent beta-lactam dosing in critically ill patients with sepsis: A randomized controlled trial.

Applied for and awaiting approval0 个研究点目标入组 408 人开始时间: 2019年11月27日最近更新:
适应症

试验速览

阶段
未知
状态
尚未招募
发起方
入组人数
408

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
1 Month(s) 至 23 Month(s)(—)
性别
All

入选标准

  • All patients, adult and paediatric, admitted to the intensive care unit with sepsis
  • Prescription of one of four beta lactam antibiotics by treating doctor:
  • 1.Amoxicillin- clavulanate
  • 2.Piperacillin-tazobactam
  • 3.Meropenem
  • 4.Imipenem
  • Anticipated ICU at least 48 hours.

排除标准

  • Less than 1 month old
  • Chronic renal failure (eGFR<30ml/min)
  • Patient admitted and already on renal replacement therapy
  • Inadequate intravenous access
  • Infections in which standard recommended antibiotic duration is > 14 days (eg: infective endocarditis, osteomyelitis)
  • Patients receiving palliative care at study assessment
  • Patient previously enrolled on this study
  • Declined consent

研究者

发起方
Applied for and awaiting approval

相似试验

Continuous vs. intermittent beta-lactam dosing in... | 临床试验